CERO THERAPEUTICS HOLDINGS I (CERO) Stock Overview
NASDAQ:CERO - US71902K4022 - Common Stock
CERO Key Statistics, Chart & Performance
The current stock price of CERO is 7.82 USD. In the past month the price increased by 7.34%. In the past year, price decreased by -96.95%.
CERO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.64 | 367.44B | ||
| AMGN | AMGEN INC | 13.18 | 154.79B | ||
| GILD | GILEAD SCIENCES INC | 14.75 | 141.65B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.96 | 99.71B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.87 | 62.28B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 59.58B | ||
| ARGX | ARGENX SE - ADR | 76.21 | 43.24B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.02 | 35.47B | ||
| INSM | INSMED INC | N/A | 28.26B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.57B | ||
| NTRA | NATERA INC | N/A | 22.54B | ||
| BIIB | BIOGEN INC | 8.51 | 19.97B |
Related stock screener links
About CERO
Company Profile
CERo Therapeutics Holdings Inc is a US-based company operating in Biotechnology industry. The company is headquartered in South San Francisco, California and currently employs 8 full-time employees. The company went IPO on 2021-10-06. CERo Therapeutics Holdings, Inc. is an immunotherapy company advancing the development of engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body’s full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is designed to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating what the Company refers to as Chimeric Engulfment Receptor T cells (CER-T). Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand. The firm is initiating clinical trials for its lead product candidate, CER-1236, for hematological malignancies.
Company Info
CERO THERAPEUTICS HOLDINGS I
201 Haskins Way, Suite 230
South San Francisco CALIFORNIA US
Employees: 8
Phone: 6504072376
CERO THERAPEUTICS HOLDINGS I / CERO FAQ
What is the stock price of CERO THERAPEUTICS HOLDINGS I today?
The current stock price of CERO is 7.82 USD. The price increased by 0.9% in the last trading session.
What is the ticker symbol for CERO THERAPEUTICS HOLDINGS I stock?
The exchange symbol of CERO THERAPEUTICS HOLDINGS I is CERO and it is listed on the Nasdaq exchange.
On which exchange is CERO stock listed?
CERO stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CERO THERAPEUTICS HOLDINGS I stock?
8 analysts have analysed CERO and the average price target is 45.9 USD. This implies a price increase of 486.96% is expected in the next year compared to the current price of 7.82. Check the CERO THERAPEUTICS HOLDINGS I stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CERO THERAPEUTICS HOLDINGS I worth?
CERO THERAPEUTICS HOLDINGS I (CERO) has a market capitalization of 4.07M USD. This makes CERO a Nano Cap stock.
How many employees does CERO THERAPEUTICS HOLDINGS I have?
CERO THERAPEUTICS HOLDINGS I (CERO) currently has 8 employees.
What are the support and resistance levels for CERO THERAPEUTICS HOLDINGS I (CERO) stock?
CERO THERAPEUTICS HOLDINGS I (CERO) has a support level at 6.87 and a resistance level at 7.8. Check the full technical report for a detailed analysis of CERO support and resistance levels.
Should I buy CERO THERAPEUTICS HOLDINGS I (CERO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CERO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CERO, evaluating the profitability, health, valuation and growth aspects
- CERO THERAPEUTICS HOLDINGS I (CERO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CERO THERAPEUTICS HOLDINGS I (CERO) Sales and EPS estimates to see what analysts future expectations are.
- CERO THERAPEUTICS HOLDINGS I (CERO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CERO THERAPEUTICS HOLDINGS I (CERO) Insider and Institutional Ownership to learn about the owners and their transactions.
- CERO THERAPEUTICS HOLDINGS I (CERO) Stock Chart to make your own analysis
- CERO THERAPEUTICS HOLDINGS I (CERO) Latest news and press-releases to stay up to date.
Does CERO THERAPEUTICS HOLDINGS I (CERO) stock pay dividends?
CERO does not pay a dividend.
What is the Price/Earnings (PE) ratio of CERO THERAPEUTICS HOLDINGS I (CERO)?
CERO THERAPEUTICS HOLDINGS I (CERO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-377.43).
What is the Short Interest ratio of CERO THERAPEUTICS HOLDINGS I (CERO) stock?
The outstanding short interest for CERO THERAPEUTICS HOLDINGS I (CERO) is 10.23% of its float. Check the ownership tab for more information on the CERO short interest.
CERO Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to CERO. When comparing the yearly performance of all stocks, CERO is a bad performer in the overall market: 97.93% of all stocks are doing better.
CERO Financial Highlights
Over the last trailing twelve months CERO reported a non-GAAP Earnings per Share(EPS) of -377.43. The EPS increased by 35.88% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -178.24% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
CERO Forecast & Estimates
8 analysts have analysed CERO and the average price target is 45.9 USD. This implies a price increase of 486.96% is expected in the next year compared to the current price of 7.82.